Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens

Poulakou, Garyphallia; Kontopidou, Flora; Paramythiotou, Elisabeth; Kompoti, Maria; Katsiari, Maria; Mainas, Efstratios; Nicolaou, Chara; Yphantis, Dimitrios; Antoniadou, Anastasia; Trikka-Graphakos, Eleftheria; Roussou, Zoi; Clouva, Phyllis; Maguina, N; Kanellakopoulou, Kyriaki; Armaganidis, Apostolos; Giamarellou, Helen

doi:10.1016/j.jinf.2009.02.009

Cited by 96 publications

(82 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, colistin-resistant variants of the international KPC + ST258 K. pneumoniae strain are circulating in Greece and Hungary [13,14], with a few cases also seen in the UK. In the case of tigecycline, there are positive case reports of its use in infections due to K. pneumoniae with VIM and KPC carbapenemases in Greece [15], but also of resistance emerging during therapy, albeit in an off-label setting (nosocomial pneumonia) [16]. Moreover, it is licensed for use only in intra-abdominal and complicated skin and skin-structure infections, and proved inferior to imipenem/cilastatin in ventilator-associated pneumonia, providing a caution against off-label use in this infection [17].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline

Livermore¹,

Warner²,

Mushtaq³

et al. 2011

International Journal of Antimicrobial Agents

304

181

View full text Add to dashboard Cite

Section: Accepted Manuscriptmentioning

confidence: 99%

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline

Livermore¹,

Warner²,

Mushtaq³

et al. 2011

International Journal of Antimicrobial Agents

304

181

View full text Add to dashboard Cite

“…The emergence and spread of colistin and tigecycline resistance among carbapenemase-producing A. baumannii limits the therapeutic options for patients who are infected with this organism (Karaiskos and Giamarellou 2014;Mendes et al, 2010;Poulakou et al 2009;Reis et al, 2003). Colistin resistance is associated with specific modification of the lipid A component of the outer membrane and is mediated by mutations in specific regions of the two-component regulation systems pmrA/B and phoP/Q (Beceiro et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Molecular identification of tigecycline- and colistin-resistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013

Mavroidi¹,

Likousi²,

Palla³

et al. 2015

Journal of Medical Microbiology

Self Cite

View full text Add to dashboard Cite

An alarming increase in the resistance rates of tigecycline and colistin among carbapenemaseproducing Acinetobacter baumannii recovered from a Greek hospital over a 3-year period (2011-2013) was investigated. The antimicrobial resistance profiles and carbapenemase gene content were determined for a collection of colistin-and/or tigecycline-resistant carbapenemase-producing A. baumannii isolates (n542), which were recovered consecutively during the study period. A gradual increase in the incidence of bla OXA-23 producers was observed from 2011 to 2013. A cluster of 21 isolates comprised tigecycline-resistant bla OXA-23 producers displayed a single antimicrobial resistance pattern. The emergence of two bla OXA-23 producers resistant to both tigecycline and colistin was documented. Furthermore, determination of the mechanisms of colistin and tigecycline resistance and molecular typing by the tri-locus sequence typing (3LST) scheme for nine isolates recovered from bloodstream infections were performed. Out of nine isolates, five tigecycline-and two colistin-resistant isolates were bla OXA-23 producers of 3LST ST101 corresponding to the international clone II recovered during 2012-2013. All nine isolates were positive for the presence of the adeB gene of the AdeABC efflux pump. Three colistin-resistant isolates possessed novel substitutions in PmrB, which may be implicated in colistin resistance. To the best of our knowledge, this is the first report of the acquisition of tigecycline and colistin resistance among bla OXA-23 -producing A. baumannii of 3LST ST101 in Greece; thus, continuous surveillance and molecular characterization, prudent use of antibiotics and implementation of infection control measures for A. baumannii are urgent.

show abstract

“…are another concern. 32,56 Nevertheless, tigecycline was used at standard dosage, in combination with an anti-pseudomonal drug (β-lactams, quinolones, aminoglycosides) in 110 adult cancer patients (58% with hematological malignancies and 24% post-HSCT) as salvage therapy, for the treatment of refractory pneumonia (60%), bacteremia (17%) or other infections, which were microbiologically documented in 45% of the patients. 57 Not all isolates were susceptible, or were tested to the antibiotics administered, concurrently with the tigecycline.…”

Section: Tigecyclinementioning

confidence: 99%

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

et al. 2013

View full text Add to dashboard Cite

The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4 th European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o n 2 0 1 3organizing committee and experts were solicited to form the working group. The group reviewed the published English-language literature and prepared proposals on treatment options for infections due to resistant bacteria. Papers for review were sought using PubMed with the terms "linezolid", "daptomycin", "quinupristin/ dalfopristin", "colistin or polymyxin", "tigecycline", "fosfomycin", "telavancin", "ceftaroline" AND "stem cell transplantation or bone marrow transplant or leukemia or hematological malignancy or cancer". References cited in the articles identified were also considered. In respect of 'Duration of therapy', the main search terms used were "antibiotic therapy"; "stem cell transplantation or bone marrow transplantation or hematological malignancy or cancer"; "febrile neutropenia" and "duration therapy", "discontinuation antibiotics" and "microbiologically documented infection". Definitions of resistanceA bacterial isolate was considered non-susceptible if it was categorized resistant, intermediate or non-susceptible when using clinical breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical and Laboratory Standards Institute (CLSI) or the US Food and Drug Administration (FDA). Definitions of 'MDR' vary among authors and usually presume resistance to at least two antibiotics used in empiric therapy (3 rd 4 th -generation cephalosporins, carbapenems or piperacillin/tazobactam) or resistance to at least three of the following antibiotic classes: antipseudomonal penicillins, cephalosporins, carbapenems, aminoglycosides and fluoroquinolones. [11][12][13][14][15] According to the recent definition of the European Centre for Disease Prevention and Control...

show abstract

Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens

Cited by 96 publications

References 31 publications

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline

Molecular identification of tigecycline- and colistin-resistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

Contact Info

Product

Resources

About